Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The DNA gyrase subunit A C-terminal domain (GyrA CTD) is an essential structural and functional component of bacterial DNA gyrase, the only enzyme capable of introducing negative supercoils into DNA. It possesses a unique 'beta-pinwheel' fold that enables the enzyme to bind and wrap the DNA substrate, a critical prerequisite for the strand-passage reaction that alters DNA topology. By facilitating this wrapping, the GyrA CTD ensures the correct orientation of the G-segment and T-segment of DNA, allowing for efficient supercoiling during replication and transcription. This domain is a major focus for antibacterial drug development because its specific structural architecture is absent in eukaryotic topoisomerases, providing a high degree of therapeutic selectivity. While classic fluoroquinolones primarily target the catalytic N-terminal domain and its interface with GyrB, the CTD is a target for novel inhibitors like Simocyclinone D8, which block the initial DNA-binding and wrapping steps. Mutations within the GyrA CTD or the nearby Quinolone Resistance-Determining Region (QRDR) are primary drivers of clinical antibiotic resistance, necessitating ongoing research into this domain's structural dynamics.
Inhibition of the DNA wrapping mechanism essential for negative supercoiling; stabilization of the covalent enzyme-DNA cleavage complex leading to double-strand breaks; prevention of DNA binding to the gyrase complex.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA gyrase subunit A C-terminal domain (GyrA CTD).